BioDot
Private Company
Funding information not available
Overview
BioDot is a privately-held, revenue-generating company and the established market leader in automated ultra-low volume liquid dispensing. Its core technology platform enables the precise deposition of minute fluid volumes, which is critical for manufacturing advanced lateral flow assays, biosensors, microfluidic devices, and for life science research applications like PCR miniaturization and cytogenetics. With over 5,600 platforms installed in 62 countries, BioDot has a significant global installed base and is leveraging this position to launch next-generation systems like the NANOlab™, targeting continued growth in the expanding diagnostics and precision life sciences tools markets.
Technology Platform
Proprietary "Discrete Droplet Dispensing™" technology enabling non-contact, automated, high-throughput liquid dispensing across microliter, nanoliter, and picoliter (as low as 25 pL) volumes. Core technologies include BioJet™ and Rainmaker™, integrated into application-specific platforms for diagnostics manufacturing and life science research.
Opportunities
Risk Factors
Competitive Landscape
BioDot competes in the precision liquid handling market, claiming leadership in ultra-low volume dispensing for diagnostics manufacturing. Competitors include other specialized dispensing companies and broader life science instrumentation players like Tecan, PerkinElmer, and Revvity, which offer liquid handling solutions that may overlap in certain applications. BioDot's deep focus and large installed base in diagnostics are key differentiators.